Table 3.

Serious adverse events

Dose, mg/kgNumber of patients/number of cohort (n = 17)SAEs (n = 34)
0.52/4Increased blood creatinine, dehydration, fatigue, decreased GFR, neoplasm (disease progression)
1.51/3Neoplasm (disease progression)
5.04/14Abdominal pain, diarrhea, device-related infection, urinary tract infection, cholangitis, urinary tract obstruction
10.01/3Neoplasm (disease progression)
15.06/13Hypoglycemia, decreased weight,a decreased appetite,a urosepsis, small intestine obstruction, hypercalcemia, bacteremia, device-related infection, confusional state, hemoptysis, deep vein thrombosis
30.00/3
45.03/3Abdominal distention, abdominal pain, vomiting, musculoskeletal chest pain, neoplasm (disease progression), renal failure, respiratory failure

Abbreviation: GFR, glomerular filtration rate.

  • aConsidered by investigators to be treatment related; occurred in the same patient.